Literature DB >> 25026612

Rising rates of carbapenem-resistant enterobacteriaceae in community hospitals: a mixed-methods review of epidemiology and microbiology practices in a network of community hospitals in the southeastern United States.

Joshua T Thaden1, Sarah S Lewis, Kevin C Hazen, Kirk Huslage, Vance G Fowler, Rebekah W Moehring, Luke F Chen, Constance D Jones, Zack S Moore, Daniel J Sexton, Deverick J Anderson.   

Abstract

OBJECTIVE: Describe the epidemiology of carbapenem-resistant Enterobacteriaceae (CRE) and examine the effect of lower carbapenem breakpoints on CRE detection.
DESIGN: Retrospective cohort.
SETTING: Inpatient care at community hospitals. PATIENTS: All patients with CRE-positive cultures were included.
METHODS: CRE isolated from 25 community hospitals were prospectively entered into a centralized database from January 2008 through December 2012. Microbiology laboratory practices were assessed using questionnaires.
RESULTS: A total of 305 CRE isolates were detected at 16 hospitals (64%). Patients with CRE had symptomatic infection in 180 cases (59%) and asymptomatic colonization in the remainder (125 cases; 41%). Klebsiella pneumoniae (277 isolates; 91%) was the most prevalent species. The majority of cases were healthcare associated (288 cases; 94%). The rate of CRE detection increased more than fivefold from 2008 (0.26 cases per 100,000 patient-days) to 2012 (1.4 cases per 100,000 patient-days; incidence rate ratio (IRR), 5.3 [95% confidence interval (CI), 1.22-22.7]; P = .01). Only 5 hospitals (20%) had adopted the 2010 Clinical and Laboratory Standards Institute (CLSI) carbapenem breakpoints. The 5 hospitals that adopted the lower carbapenem breakpoints were more likely to detect CRE after implementation of breakpoints than before (4.1 vs 0.5 cases per 100,000 patient-days; P < .001; IRR, 8.1 [95% CI, 2.7-24.6]). Hospitals that implemented the lower carbapenem breakpoints were more likely to detect CRE than were hospitals that did not (3.3 vs 1.1 cases per 100,000 patient-days; P = .01).
CONCLUSIONS: The rate of CRE detection increased fivefold in community hospitals in the southeastern United States from 2008 to 2012. Despite this, our estimates are likely underestimates of the true rate of CRE detection, given the low adoption of the carbapenem breakpoints recommended in the 2010 CLSI guidelines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25026612      PMCID: PMC4217156          DOI: 10.1086/677157

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  12 in total

1.  Comparison of BD Phoenix, Vitek 2, and MicroScan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae.

Authors:  Neil Woodford; Anne T Eastaway; Michael Ford; Alistair Leanord; Chloe Keane; Reinhard M Quayle; Jane A Steer; Jiancheng Zhang; David M Livermore
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

2.  Emergence of extended-spectrum beta-lactamase-producing Escherichia coli in community hospitals throughout North Carolina: a harbinger of a wider problem in the United States?

Authors:  Joshua T Freeman; Daniel J Sexton; Deverick J Anderson
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

3.  The urgent need for new antibacterial agents.

Authors:  Richard Wise
Journal:  J Antimicrob Chemother       Date:  2011-06-23       Impact factor: 5.790

Review 4.  Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention.

Authors:  Neil Gupta; Brandi M Limbago; Jean B Patel; Alexander J Kallen
Journal:  Clin Infect Dis       Date:  2011-07-01       Impact factor: 9.079

5.  The network approach for prevention of healthcare-associated infections: long-term effect of participation in the Duke Infection Control Outreach Network.

Authors:  Deverick J Anderson; Becky A Miller; Luke F Chen; Linda H Adcock; Evelyn Cook; A Lynn Cromer; Susan Louis; Paul A Thacker; Daniel J Sexton
Journal:  Infect Control Hosp Epidemiol       Date:  2011-04       Impact factor: 3.254

6.  Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia.

Authors:  Abraham Borer; Lisa Saidel-Odes; Klaris Riesenberg; Seada Eskira; Nejama Peled; Ronit Nativ; Francisc Schlaeffer; Michael Sherf
Journal:  Infect Control Hosp Epidemiol       Date:  2009-10       Impact factor: 3.254

7.  Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections.

Authors:  George L Daikos; Panayiotis Petrikkos; Mina Psichogiou; Chris Kosmidis; Evangelos Vryonis; Athanasios Skoutelis; Kleoniki Georgousi; Leonidas S Tzouvelekis; Panayotis T Tassios; Christina Bamia; George Petrikkos
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

8.  Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies.

Authors:  Gopi Patel; Shirish Huprikar; Stephanie H Factor; Stephen G Jenkins; David P Calfee
Journal:  Infect Control Hosp Epidemiol       Date:  2008-12       Impact factor: 3.254

9.  Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae.

Authors:  K F Anderson; D R Lonsway; J K Rasheed; J Biddle; B Jensen; L K McDougal; R B Carey; A Thompson; S Stocker; B Limbago; J B Patel
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

10.  The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.

Authors:  Michael Y Lin; Rosie D Lyles-Banks; Karen Lolans; David W Hines; Joel B Spear; Russell Petrak; William E Trick; Robert A Weinstein; Mary K Hayden
Journal:  Clin Infect Dis       Date:  2013-08-14       Impact factor: 9.079

View more
  49 in total

Review 1.  Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods.

Authors:  Roberto Viau; Karen M Frank; Michael R Jacobs; Brigid Wilson; Keith Kaye; Curtis J Donskey; Federico Perez; Andrea Endimiani; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

2.  Evaluation of the Carba NP Test in Oregon, 2013.

Authors:  Karim E Morey; Robert Vega; P Maureen Cassidy; Genevieve L Buser; Jaipreet K Rayar; Jeffrey A Myers; Scott J Weissman; Zintars G Beldavs; Christopher D Pfeiffer
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Rapid Direct Susceptibility Testing from Positive Blood Cultures by the Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry-Based Direct-on-Target Microdroplet Growth Assay.

Authors:  Evgeny A Idelevich; Luise M Storck; Katrin Sparbier; Oliver Drews; Markus Kostrzewa; Karsten Becker
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

4.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

Authors:  Andre C Kalil; Mark L Metersky; Michael Klompas; John Muscedere; Daniel A Sweeney; Lucy B Palmer; Lena M Napolitano; Naomi P O'Grady; John G Bartlett; Jordi Carratalà; Ali A El Solh; Santiago Ewig; Paul D Fey; Thomas M File; Marcos I Restrepo; Jason A Roberts; Grant W Waterer; Peggy Cruse; Shandra L Knight; Jan L Brozek
Journal:  Clin Infect Dis       Date:  2016-07-14       Impact factor: 9.079

5.  Continuing Challenges for the Clinical Laboratory for Detection of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Romney M Humphries; James A McKinnell
Journal:  J Clin Microbiol       Date:  2015-10-14       Impact factor: 5.948

6.  Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States.

Authors:  S M Bartsch; J A McKinnell; L E Mueller; L G Miller; S K Gohil; S S Huang; B Y Lee
Journal:  Clin Microbiol Infect       Date:  2016-09-15       Impact factor: 8.067

7.  The Economic Value of the Centers for Disease Control and Prevention Carbapenem-Resistant Enterobacteriaceae Toolkit.

Authors:  Sarah M Bartsch; Susan S Huang; James A McKinnell; Kim F Wong; Leslie E Mueller; Loren G Miller; Bruce Y Lee
Journal:  Infect Control Hosp Epidemiol       Date:  2018-03-19       Impact factor: 3.254

8.  Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) in brain and spinal cord injury patients: potential for prolonged colonization.

Authors:  N R Zembower; A Zhu; M Malczynski; C Qi
Journal:  Spinal Cord       Date:  2016-10-18       Impact factor: 2.772

9.  The pros, cons, and unknowns of search and destroy for carbapenem-resistant enterobacteriaceae.

Authors:  Prashini Moodley; Andrew Whitelaw
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

Review 10.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.